Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea

Pediatric Hematology and Oncology

Volumn 18, Issue 6, 2001, Pages 371-376

  Moschovi, M ^a   Psychou, F ^a   Menegas, D ^a   Tsangaris, G Th ^a   Tzortzatou Stathopoulou, F ^a   Nikolaidou, P ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Childhood; Hodgkin's disease; Hydroxyurea; Sickle cell disease

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; HEMOGLOBIN F; HYDROXYUREA; IRON CHELATE; VINBLASTINE;

ARTICLE; BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CARCINOGENESIS; CASE REPORT; DRUG CARCINOGENICITY; DRUG EFFECT; DRUG INDUCED CANCER; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE ADHESIVENESS; FOLLOW UP; HODGKIN DISEASE; HUMAN; LEUKEMOGENESIS; LYMPHOCYTE; SCHOOL CHILD; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; VASCULAR ENDOTHELIUM;

ANEMIA, SICKLE CELL; BETA-THALASSEMIA; BONE MARROW TRANSPLANTATION; CHILD; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; HYDROXYUREA; MALE; REMISSION INDUCTION;

EID: 0034830942     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/088800101316921985     Document Type: Article

References (23)

1. Pain in sickle cell disease: Rates and risk factors
2. Acute chest syndrome in sickle cell disease: Clinical presentation and course
3. Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia
4. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea
5. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients
6. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea
7. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy
8. Hydroxyurea therapy in children severely affected with sickle cell disease
9. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia
10. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: Implications for pharmacological intervention
11. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial
12. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial
13. Mortality in sickle cell disease: Life expectancy and risk factors for early death
14. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease
15. Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/β-thalassaemia
16. An overview of the clinical experience with hydroxyurea
17. Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years
18. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications
19. Lymphoma transformation in polycythemia vera treated with hydroxyurea
20. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocytopenia treated with hydroxyurea: High proportion of cases with 17p deletions
21. Essential thrombocythemia and acute leukemia
22. Acute myeloid leukemia evolving from essential thrombocythemia in two patients with hydroxyurea
23. Fetal hemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease